Aurobindo Pharma's Unit-VII Classified as Voluntary Action Indicated Following US FDA Inspection
Aurobindo Pharma Ltd. reported on May 6, 2026, that the United States Food and Drug Administration (US FDA) has classified its Unit-VII facility as "Voluntary Action Indicated" (VAI). The facility, which manufactures oral solid dosage units, has concluded the inspection process.The inspection of Unit-VII, located at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana, took place from January 28 to February 10, 2026.
Upon the conclusion of the inspection, the company reported that a 'Form 483' was issued, detailing a total of nine observations.
Aurobindo Pharma Ltd. confirmed that the facility has now received the Establishment Inspection Report (EIR), classifying the unit as "Voluntary Action Indicated" (VAI). The FDA has officially concluded that the inspection process is now closed.
AUROPHARMA Stock Price Movement
Shares of AUROBINDO PHARMA LIMITED are edging higher to ₹1431 as of the 9:14 AM pre-open session, gaining 0.20%. The stock is experiencing early activity, registering a volume of 2,515 shares traded in the pre-open session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.